Sphere Fluidics unveils next-generation single-cell analysis platform
Cambridge-based Sphere Fluidics has announced the development of Cyto-Mine Chroma, an advanced iteration of its Cyto-Mine platform for single-cell analysis and isolation. Set to launch in Q1 2025, the new system aims to enhance workflow efficiency in biotherapeutic discovery and development.
Enhanced capabilities
The Cyto-Mine Chroma builds upon its predecessor’s picodroplet technology, which encapsulates individual cells for functional assessment and isolation. The platform’s upgrade to a four-colour laser and detector system significantly expands its analytical capabilities, allowing researchers to examine multiple targets within each encapsulated cell.
A key feature of the Cyto-Mine Chroma is its ability to perform multiplexed assays. The company’s first multiplexed assay kit will enable simultaneous analysis of cell viability, productivity, and target specificity within a single droplet. This advancement is expected to streamline clone selection processes, potentially reducing project timelines from months to weeks.
Applications in biotherapeutics
The new platform is designed to support a wide range of applications in single-cell analysis, including antibody discovery and cell line development. Sphere Fluidics also anticipates its use in emerging fields such as cell therapy.
Richard Hammond, CTO at Sphere Fluidics, said: “By combining multiplexing with our best-in-class cell throughput for functional screening of viable cells, the Cyto-Mine Chroma platform will be a powerful new
tool for our customers and will help them shave months off their project timelines.”
Future developments
Sphere Fluidics has indicated that the Cyto-Mine Chroma is designed with future expansion in mind. The company’s product roadmap includes plans for new assays and applications, with the potential for additional capabilities
to be incorporated via upgrade modules.
For more information, visit: https://spherefluidics.com/our-products/platform-products/cyto-mine-chroma
Digital issue: Please click here for more information
